Staff Investigators

提议两名工作人员调查员担任临床副副主任 研究。肺癌新疗法开发专家Afshin Dowlati博士和John博士 斯威特纳姆是淋巴瘤治疗方面的专家，两人都是经验丰富的临床研究人员 具有相当强的领导能力，能够协调临床试验研究，强调由研究人员发起 努力。作为工作人员研究员，他们将有集中的时间致力于临床试验的开发和 监督，特别强调研究人员发起的试验，这些试验跨越科学计划，涉及 病例ccc临床试验疾病团队。作为工作人员调查员，他们将有突出的地位和 授权协助调查人员制定和设计协议，并通过以下方式进行高效、安全的管理 在药物开发的早期阶段有高度的质量保证。

Two staff investigators are proposed, both to serve in the function as Deputy Associate Directors for Clinical Research. Dr. Afshin Dowlati, an expert in novel therapeutic development in lung cancer, and Dr. John Sweetenham, an expert in lymphoma therapeutics, are both accomplished clinical investigators with considerable leadership capacity to coordinate clinical trials research emphasizing investigator-initiated efforts. As staff investigators, they will have focused time to devote to clinical trials development and oversight with special emphasis on investigator-initiated trials that cut across scientific programs and involve the Case CCC clinical trials disease teams. As staff investigators, they will have the prominence and authority to assist investigators in protocol development and design, and in efficient, safe management with a high degree of quality assurance during early phase drug development.